Company Description
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally.
The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.
It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags.
The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services.
It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.
| Country | United States |
| Founded | 1987 |
| IPO Date | Nov 22, 1989 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 414 |
| CEO | Roderick de Greef |
Contact Details
Address: 3303 Monte Villa Parkway, Suite 310 Bothell, Washington 98021 United States | |
| Phone | 425 402 1400 |
| Website | biolifesolutions.com |
Stock Details
| Ticker Symbol | BLFS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000834365 |
| CUSIP Number | 09062W204 |
| ISIN Number | US09062W2044 |
| Employer ID | 94-3076866 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Roderick de Greef | Chief Executive Officer and Chairman |
| Troy Wichterman | Chief Financial Officer |
| Karen Foster | Chief Quality and Operations Officer |
| Dr. Aby J. Mathew Ph.D. | Chairman of Scientific Advisory Board, Executive Vice President and Chief Scientific Officer |
| Todd Berard | Chief Marketing Officer |
| Sarah Aebersold J.D. | Chief Human Resources Officer |
| Garrie Richardson B.Sc., M.B.A. | Chief Revenue Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 1, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Sep 18, 2024 | 144 | Filing |
| Aug 19, 2024 | 144 | Filing |
| Aug 9, 2024 | 10-Q | Quarterly Report |
| Aug 9, 2024 | 8-K/A | [Amend] Current report |
| Aug 8, 2024 | 8-K | Current Report |
| Aug 6, 2024 | 8-K | Current Report |
| Jul 26, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jun 5, 2024 | DEF 14A | Other definitive proxy statements |
| May 10, 2024 | 10-Q | Quarterly Report |